The upcoming Clinical Trials in Rare Diseases conference will cover the most concerning challenges in rare disease research.

The deal is part of a wider $55bn investment strategy by J&J to bolster US manufacturing amid pressure from Trump.

Padcev-Keytruda will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Keros received orphan drug designation from the US FDA for its investigational therapy KER-065 to treat Duchenne muscular dystrophy (DMD).